- Neil Jones has been the new Chief Commercial Officer (CCO) of Aenova Group since July 18, 2022.
- As a member of the Executive Leadership Team (ELT), he will play a key role in shaping the future and commercial success of Aenova Group and will report directly to CEO Jan Kengelbach in his role.
Starnberg, August 04, 2022 – As of July 18, 2022, Neil Jones has joined Aenova as the new Chief Commercial Officer (CCO) of the Aenova Group. As a member of the Executive Leadership Team (ELT), he manages Aenova’s commercial operations and will play a key role in shaping and expanding them. “I am very happy to now become part of Aenova’s success story,” commented Jones on his start at Aenova. “Together with my new colleagues, we will ensure and further expand the international success of the Aenova Group and best position the organization for future challenges in the competitive CDMO market environment.”
Neil has extensive experience in the pharmaceutical and biotechnology industries in both product and service areas. Prior to joining Aenova, he was Vice President at Catalent Pharma Solutions and CEO and CBO at VMIC (Vaccine Manufacturing and Innovation Centre). Prior to that, he served as Director of Business Development Europe at Catalent Pharma Solutions from 2016 to 2021 and previously held various positions at Patheon. Neil holds a Bachelor of Science in Chemistry from the University of Bristol and a Post Graduate Certificate in Management from the University of the West of England.
“We are very pleased to welcome Neil to the team. Neil is a manager who is highly experienced in the pharmaceutical-biotechnology industry and is perfectly placed for the central position of CCO at Aenova,” commented CEO Jan Kengelbach on the appointment. “Neil will greatly enrich our team with his drive, his innovative ability and last but not least with his personal and human values.”
About Aenova Group
The Aenova Group is a leading global contract manufacturer and development service provider for the pharmaceutical and healthcare industry. As a one-stop store, Aenova develops, produces and packages all common dosage forms, product groups and active ingredient classes from pharmaceuticals to dietary supplements for human and animal health: solid, semi-solid and liquid, sterile and non-sterile, high and low dose, OEB 1 to 5 (Occupational Exposure Band). Around 4,200 employees at 16 sites in Europe and the USA contribute to the success of the Aenova Group. www.aenova-group.com.
Dr. Susanne Knabe
Head of Corporate Communication & PR
Aenova Holding GmbH
Berger Straße 8 – 10
Mobile: +49 170 22 368 42